Soligenix, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2012. Soligenix is a development-stage biopharmaceutical company with BioTherapeutics and Vaccines/BioDefense segments. Its programs include oral beclomethasone dipropionate (BDP), RiVax, VeloThrax, OrbeShield and the ThermoVax vaccine-stabilization platform.
Financial results and condition
| Metric | Q3 2012 | Q3 2011 | Nine months 2012 | Nine months 2011 |
|---|---|---|---|---|
| Revenue | $931,627 | $5,795,862 | $2,341,896 | $7,009,987 |
| Gross profit | $169,999 | $5,140,737 | $407,367 | $5,451,014 |
| Operating loss/income | $(760,216) | $2,203,463 | $(3,182,883) | $(1,452,173) |
| Net loss/income | $(758,966) | $2,204,874 | $(3,177,599) | $(1,446,854) |
| Net loss/income per share | $(0.07) | $0.20 | $(0.29) | $(0.13) |
- Revenue was primarily NIH grant revenue in 2012; 2011 included a $5 million upfront Sigma-Tau payment for European licensing rights. The comparison therefore reflects a significant prior-year one-time license payment.
- Gross margin was approximately 18% in Q3 2012 and 17% for the first nine months, compared with approximately 89% and 78% in the respective 2011 periods, largely because of the 2011 license payment.
- Research and development expense was $371,338 for Q3 and $1,749,112 for the first nine months, down from $2,342,253 and $5,228,779, respectively. Management attributed the decline to the prior-year license-related sublicense fee and reduced spending after discontinuing the confirmatory Phase 3 orBec trial for acute GI GVHD.
- Cash and cash equivalents were $3,698,398 at September 30, 2012, down 38% from $5,996,668 at December 31, 2011. Working capital was $3,094,649, down from $5,696,444.
- Operating cash use was $2,293,515 for the nine months, compared with $730,131 in the prior-year period. Investing cash use was $4,755; there was no financing cash flow in 2012. Cash declined by $2,298,270 overall.
- Total assets were $5,073,060 and shareholders’ equity was $4,021,217 at September 30. Current liabilities were $1,051,843, consisting of accounts payable and accrued compensation. The balance sheet reports no debt.
Changes, outlook and notable items
- Management said existing cash, grant-funded programs, cost reductions and expected New Jersey tax-certificate proceeds were expected to fund working capital and capital expenditures into the fourth quarter of 2013. This outlook depends on those funding and cost assumptions; the company was evaluating additional equity financing and stated that financing might not be available on favorable terms or at all.
- Approximately $4.6 million in active grant funding remained available to support research programs into 2014. Management expected approximately $2.4 million of grant revenue over the next 12 months and forecast approximately $3.2 million of R&D spending before grant reimbursements.
- Management described a cost-reduction plan that included headcount reductions and continued efforts to reduce costs. The company also expected to continue using equity instruments to compensate some vendors and collaboration partners.
- Development plans included initiating a Phase 1/2 study of SGX203 for pediatric Crohn’s disease, subject to funding; a Phase 2 study of orBec for chronic GI GVHD supported by a newly awarded $300,000 NIH grant; and further preclinical work on OrbeShield, supported by an approximately $600,000 NIAID grant. The SGX201 Phase 1/2 radiation-enteritis trial was complete, with safety and preliminary efficacy findings under review.
- The company reported a prior Phase 3 orBec trial for acute GI GVHD had been discontinued. Sigma-Tau’s remaining potential milestones were stated as up to $9 million under the North American agreement and an aggregate $11 million under the European amendment; payments are contingent on milestone achievement.
- Commitments included approximately $325,000 under licensing agreements, potentially payable upon clinical or commercial success, and total scheduled contractual obligations of $581,096 through 2016. No assurance of clinical or commercial success was provided.
- The company completed a 1-for-20 reverse stock split on February 1, 2012. Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Whether cash, remaining grant funds, cost reductions and anticipated New Jersey tax-certificate proceeds support the stated runway into Q4 2013, and whether additional financing is required.
- Current timing, funding and regulatory status of the planned SGX203 and orBec clinical programs, including the implications of the discontinued Phase 3 trial.
- Availability and timing of grant reimbursements and whether new grant applications or awards are needed to sustain development spending.
- Conditions and likelihood of Sigma-Tau milestone payments and future royalties, which depend on development, approval and commercial milestones.
- Potential dilution and financing terms, given the company’s operating cash use and its stated use of equity compensation and possible equity financing.